NCT04496310 (Tele-epic) is a NA clinical trial of Telemedicine in Epilepsy, sponsored by Azienda Usl di Bologna.

Who is sponsoring NCT04496310?

NCT04496310 is sponsored by Azienda Usl di Bologna.

What drugs are being tested in NCT04496310?

Interventions in NCT04496310: Telemedicine.

What condition does NCT04496310 study?

NCT04496310 studies Epilepsy, Epileptic Encephalopathy, Refractory Epilepsy.

Is NCT04496310 still recruiting?

NCT04496310 is currently status unknown. Last updated 16 February 2022.

Last reviewed 2022-02-16 · How we verify

NCT04496310: Tele-epic

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tele-epic (Telemedicine for Epilepsy Care)

Status unknown NA Last updated 16 February 2022

What this trial tests

NA trial testing Telemedicine in Epilepsy in 600 participants. Status unknown.

Timeline

9 July 2020

Primary endpoint
8 July 2023

8 July 2023

Quick facts

Lead sponsor	Azienda Usl di Bologna
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	600
Start date	9 July 2020
Primary completion	8 July 2023
Estimated completion	8 July 2023
Sites	2 locations across Italy

Drugs / interventions tested

Telemedicine

Conditions studied

Epilepsy — all drugs for Epilepsy →
Epileptic Encephalopathy — all drugs for Epileptic Encephalopathy →
Refractory Epilepsy — all drugs for Refractory Epilepsy →

Sponsor

Azienda Usl di Bologna — full company profile →

Who can join

Eligibility, any sex, with Epilepsy or Epileptic Encephalopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Epilepsy is a chronic condition that requires consistent follow-up aimed at seizure control, surveillance of comorbidities, monitoring of antiepileptic drugs (AED) levels and side effects. Patients may encounter difficulties to be assessed adequately and the disease burden is increased by the need for travelling across the country for medical consultations. Driving restrictions are a further limit to access specialized Centers able to provide an integrated approach focused on patient needs. Telemedicine (TM) offers an invaluable support to patient follow-up, joining the sparse distribution of patients in the country with the prompt availability of a team of experts. The project assesses, through a randomized controlled trial, the non-inferiority of TM in monitoring seizure control compared to usual (face-to-face) care. This approach, coupled with a new self home-sampling method for the measurement of AED levels, will reduce health care costs and simplify patients management.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

TELEmedicine for EPIlepsy Care (TELE-EPIC): protocol of a randomised, open controlled non-inferiority clinical trial.
Licchetta L, Trivisano M, Baldin E, Mohamed S, et al · · 2021 · cited 7× · PMID 34862297 · DOI 10.1136/bmjopen-2021-053980

Verify or expand the search:

Other trials of Telemedicine

Trials testing the same drug.

NCT07059884 — Distance-Based Exercise to Preserve Function and Prevent Disability · NA · recruiting
NCT07091617 — Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer · NA · recruiting
NCT07027813 — Feasibility and Efficacy of Ambulance-Based m-Health for Pediatric Emergencies (FEAMER) Trial · NA · recruiting
NCT07124546 — Acceptance and Commitment Therapy (ACT-HBC) for the Improvement of Cancer Distress in Patients With Hepatobiliary Cancer · NA · recruiting
NCT06896539 — Telemedicine for Contraceptive Counselling- An Open Randomized Controlled Trial · NA · not yet recruiting

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other Azienda Usl di Bologna trials

Trials by the same sponsor.

NCT07492511 — Renal and Hepatic Abnormal Doppler Patterns in Trauma · recruiting
NCT06742645 — The Use of Brief Motivational Interviewing in Community Health Centers. · NA · recruiting
NCT06395558 — intErnet-based iNterventions FOR Cardiac arrEst suRvivors · NA · recruiting
NCT06471231 — Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock · Phase 4 · recruiting
NCT06750822 — Accuracy of Automatic Contusion Volume Scanning for Predicting the Incidence of Pneumonia in Patients With Thoracic Trau · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04496310 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Usl di Bologna
Last refreshed: 16 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04496310.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing